Baseline characteristics of participants by randomized group. حسب Jae-Heung Cho (798319)

الموضوعات:

Schematic diagram of entomopathogen derived copper nanoparticles (CuNPs) and their toxic effects on target and non-target species. حسب Perumal Vivekanandhan (4863484)

الموضوعات:

Results of cost-effectiveness analysis of <i>Chuna</i> manual therapy compared with usual care^a. حسب Jae-Heung Cho (798319)

الموضوعات:

Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited larvicidal activity against larvae of <i>A</i>. <i>albopictu</i> at 24 and 48h post treatment. حسب Perumal Vivekanandhan (4863484)

الموضوعات:

Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited minimal toxicity effects against <i>E</i>. <i>eugeniae</i> at 24 and 48h post treatment. حسب Perumal Vivekanandhan (4863484)

الموضوعات:

Entomopathogenic fungi-derived copper nanoparticles (CuNPs) exhibited minimal toxicity effects against <i>A</i>. <i>salina</i> at 24 and 48h post treatment. حسب Perumal Vivekanandhan (4863484)

الموضوعات:

Table2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX حسب Sofia Schaeffer (20379954)

"…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …"

Table1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.DOCX حسب Sofia Schaeffer (20379954)

"…HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. HC 86.5% vs. 92.8%, p = 0.0008) compared with HC despite comparable sleep duration. …"

PRISMA flow diagram of study selection. حسب Masoud Rahmati (16665456)

الموضوعات:

General characteristics of included studies. حسب Masoud Rahmati (16665456)

الموضوعات:

Characteristics of individual studies. حسب Masoud Rahmati (16665456)

الموضوعات:

Shares of antibiotic substances on total prescription in UTI treatment (N39.0, N30.0) by sex and age group in 2019 (female: n = 238.670 prescriptions; male: n = 40.641 prescription... حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

Shares of antibiotic substances on total prescription by quarter from 2013 to 2019 for female and male patients with UTI (N39.0, N30.0)(female: n = 1.681.255 prescriptions; male: n... حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

Shares of specialist groups prescribing 1^st, 2^nd, and 3^rd antibiotic prescriptions in UTI treatment of females (N39.0, N30.0) in 2018 and 2019. حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

Number of antibiotic prescriptions in female and male patients with UTI (N30.0 and/or N39.0). حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

Shares of antibiotic substances on total prescription in female patients with UTI (N39.0, N30.0) by physician specialties (GPs: n = 1.299.641 prescriptions; gynecologists n = 141.8... حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

Comparison of 1^st, 2^nd, and 3^rd antibiotic prescription. حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

UTI diagnoses by sex and physician specialty (2013–2019). حسب Thomas Hanslmeier (19949694)

الموضوعات: "…fluoroquinolone shares decreased…"

ONSD at T14 and six months after ICU discharge. حسب Marco Carbonara (11483575)

الموضوعات:

Middle cerebral artery mean flow velocity at three time points. حسب Marco Carbonara (11483575)

الموضوعات: